BioCentury
ARTICLE | Clinical News

Pfizer launches U.S.’s first biosimilar epoetin

November 16, 2018 5:37 PM UTC

Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen and Johnson & Johnson (NYSE:JNJ) markets Procrit.

Pfizer set Retacrit's wholesale acquisition cost (WAC) at $11.03 per 1,000 units/mL. That WAC is 57.1% below Procrit's WAC of $25.72 and 33.5% below the Epogen's $16.58 WAC...

BCIQ Company Profiles

Pfizer Inc.

BCIQ Target Profiles

Erythropoietin (EPO) receptor